Income Taxes (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
| Income Tax Disclosure [Abstract] |
|
| Schedule Components of the Company's Income Tax Expense |
The components of the Company’s income tax expense for the years ended December 31, 2025 and 2024, were as follows:
|
|
|
|
|
|
|
|
|
| |
|
2025 |
|
|
2024 |
|
Current taxes: |
|
|
|
|
|
|
|
|
Foreign |
|
$ |
8,883 |
|
|
$ |
5,252 |
|
|
|
|
|
|
|
|
|
|
Total income tax expense/(benefit) |
|
$ |
8,883 |
|
|
$ |
5,252 |
|
|
|
|
|
|
|
|
|
|
|
| Schedule of a Reconciliation of the Company's Effective Tax Rate to the U.S. Federal Statutory Income Tax Rate |
A reconciliation of the Company’s effective tax rate to the U.S. federal statutory income tax rate for the years ended December 31, 2025 and 2024, is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
2025 |
|
|
2025 |
|
|
2024 |
|
|
2024 |
|
Federal statutory rate |
|
|
1,912,292 |
|
|
|
21.00 |
% |
|
|
1,997,362 |
|
|
|
21.00 |
% |
Foreign Tax Effect |
|
|
(2,665 |
) |
|
|
0.00 |
% |
|
|
(2,719 |
) |
|
|
-0.03 |
% |
Permanent Differences |
|
|
1,934 |
|
|
|
0.00 |
% |
|
|
3,811 |
|
|
|
0.04 |
% |
Valuation allowance |
|
|
(1,794,202 |
) |
|
|
-19.70 |
% |
|
|
(1,987,047 |
) |
|
|
-20.89 |
% |
Effect of cross-border tax laws |
|
|
(7,628 |
) |
|
|
-0.10 |
|
|
|
(7,482 |
) |
|
|
-0.08 |
|
Nontaxable or nondeductible items |
|
|
(99,885 |
) |
|
|
-1.10 |
% |
|
|
(9,177 |
) |
|
|
-0.10 |
% |
Other |
|
|
(18,729 |
) |
|
|
-0.20 |
% |
|
|
— |
|
|
|
0.00 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax rate |
|
|
(8,883 |
) |
|
|
(0.1 |
)% |
|
|
(5,252 |
) |
|
|
(0.06 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Deferred Tax Assets And Liabilities |
Deferred tax assets and liabilities as of December 31, 2025 and 2024, consisted of the following:
|
|
|
|
|
|
|
|
|
| |
|
2025 |
|
|
2024 |
|
Deferred tax assets |
|
|
|
|
|
|
|
|
Net operating losses |
|
$ |
2,850,031 |
|
|
$ |
890,289 |
|
Lease liability |
|
|
205,630 |
|
|
|
215,272 |
|
Capitalized research and development |
|
|
2,589,415 |
|
|
|
2,420,060 |
|
Research and development credit |
|
|
348,597 |
|
|
|
157,265 |
|
Stock-based compensation |
|
|
18,276 |
|
|
|
20,815 |
|
Fixed Asset |
|
|
21,887 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
Total deferred tax assets |
|
|
6,033,836 |
|
|
$ |
3,703,701 |
|
|
|
|
|
|
|
|
|
|
Deferred tax liabilities |
|
|
|
|
|
|
|
|
ROU asset |
|
|
(192,565 |
) |
|
|
(207,413 |
) |
Fixed Asset |
|
|
— |
|
|
|
(246,330 |
) |
|
|
|
|
|
|
|
|
|
Total deferred tax liabilities |
|
|
(192,565 |
) |
|
|
(453,743 |
) |
|
|
|
|
|
|
|
|
|
Less: valuation allowance |
|
|
(5,841,271 |
) |
|
|
(3,249,958 |
) |
|
|
|
|
|
|
|
|
|
Total |
|
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Operating Loss Carryforwards And Tax Credit |
As of December 31, 2025, the Company had the following net operating loss (“NOL”) and tax credit carryforwards:
|
|
|
|
|
|
|
|
|
| |
|
Amount |
|
|
Expiration |
|
U.S. federal NOL |
|
$ |
7,184,853 |
|
|
|
Indefinite |
|
State (California) NOL |
|
|
19,205,159 |
|
|
|
2042-2045 |
|
California research and development credit |
|
|
441,261 |
|
|
|
2026-2030 |
|
U.S. federal research and development payroll tax credit |
|
|
692,518 |
|
|
|
2029-2030 |
|
|
| Schedule of a Reconciliation of the Beginning and Ending Amounts of Unrecognized Tax Benefits |
A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended December 31, 2025 and 2024, is as follows:
|
|
|
|
|
|
|
|
|
| |
|
2025 |
|
|
2024 |
|
Balance at beginning of year |
|
|
(35,130 |
) |
|
|
— |
|
Increase/(Decrease) for prior years |
|
|
|
|
|
|
— |
|
Increase/(Decrease) for current year |
|
|
(42,740 |
) |
|
|
(35,130 |
) |
|
|
|
|
|
|
|
|
|
Balance at end of year |
|
|
(77,870 |
) |
|
|
(35,130 |
) |
|
|
|
|
|
|
|
|
|
|